Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS)
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is:
• To provide patients with CMSaccess to amifampridine phosphate therapy until the product
becomes commercially available or development is discontinued.
The secondary objective of the study is:
• To assess the long-term safety of amifampridine phosphate in patients with CMS